Medicine and Dentistry
Patient
90%
Hematopoietic Stem Cell Transplantation
54%
Cyclophosphamide
36%
Immunosuppressive Drug
36%
Drug Therapy
27%
Combination Therapy
27%
Systemic Lupus Erythematosus
27%
Organ
27%
SLEDAI
18%
Follow up
9%
Recurrent Disease
9%
Spontaneous Remission
9%
Granulocyte Colony Stimulating Factor
9%
Thymocyte Antibody
9%
Lymphocyte
9%
Prednisone
9%
Double Stranded DNA
9%
Methylprednisolone
9%
Factor V
9%
Autologous Hematopoietic Stem Cell Transplantation
9%
Complement
9%
Conditioning
9%
Analysis
9%
Stem Cell
9%
Inpatient
9%
Therapeutic Procedure
9%
Cells
9%
Medication
9%
Death
9%
INIS
patients
100%
stem cells
72%
lupus
63%
cyclophosphamide
36%
therapy
27%
organs
27%
levels
18%
diseases
18%
complement
18%
range
9%
comparative evaluations
9%
dna
9%
performance
9%
safety
9%
death
9%
refractories
9%
grafts
9%
ablation
9%
lymphocytes
9%
colonies
9%
granulocytes
9%
durability
9%
prednisone
9%
globulins
9%
Immunology and Microbiology
Hematopoietic Stem Cell Transplantation
54%
Immunosuppressive Drug
36%
Systemic Lupus Erythematosus
36%
Cyclophosphamide
36%
Organ
27%
Lupus Erythematosus
27%
Lymphocyte
9%
Prednisone
9%
Granulocyte Colony-Stimulating Factor
9%
CD34
9%
Stem Cell
9%
Anti-Thymocyte Globulin
9%
Methylprednisolone
9%
Autologous Hematopoietic Stem Cell Transplantation
9%
Complement Blood Level
9%
Cells
9%
Immunity
9%
Conditioning
9%